294 related articles for article (PubMed ID: 24471304)
21. [Study of post marketing safety reevaluation of shenqi fuzheng injection].
Ai QH; Li YY; Xie YM
Zhongguo Zhong Yao Za Zhi; 2014 Sep; 39(18):3633-6. PubMed ID: 25532410
[TBL] [Abstract][Full Text] [Related]
22. [Analyze causes of adverse reactions induced by traditional Chinese medicine injections from its quality standards].
Cui HY; Liang AH
Zhongguo Zhong Yao Za Zhi; 2014 Mar; 39(5):934-40. PubMed ID: 25204194
[TBL] [Abstract][Full Text] [Related]
23. [Study of analysis 1 390 adverse drug reactions cases of parenterally administered dengzhan xixin based on China's spontaneous response system].
Li YY; Xiang YY; Xie YM; Shen H
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2998-3002. PubMed ID: 24471319
[TBL] [Abstract][Full Text] [Related]
24. [Core elements of safety monitoring report of medicines(Chinese patent medicines)].
Wang GQ; Liao X; Xie YM
Zhongguo Zhong Yao Za Zhi; 2016 Dec; 41(24):4483-4487. PubMed ID: 28936827
[TBL] [Abstract][Full Text] [Related]
25. [Analysis of clinical use of post-marketing hospital centralized monitoring of Xiyanping injection].
Zhao Y; Shi C; Huang P
Zhongguo Zhong Yao Za Zhi; 2016 Feb; 41(4):743-747. PubMed ID: 28871704
[TBL] [Abstract][Full Text] [Related]
26. [Explore method about post-marketing safety re-evaluation of Chinese patent medicines based on HIS database in real world].
Yang W; Xie Y; Zhuang Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2779-82. PubMed ID: 22292363
[TBL] [Abstract][Full Text] [Related]
27. [Expert consensus on the design and implementation of clinical safety centralized monitoring study of Chinese medical injection].
Zhang JH; Ren JT; Hu JQ; Xie YM; Song HB; Zhu MJ; Gao R; Wang Z; Zheng WK; Li XL; Jiang M; Huang YH; Lu F; He LY; Lian WX; Yang ZQ; Yuan WA; Hu SY; Wang BH; Wang WL; Ren DQ; Zhang BL; ;
Zhongguo Zhong Yao Za Zhi; 2017 Jan; 42(1):6-9. PubMed ID: 28945018
[TBL] [Abstract][Full Text] [Related]
28. [Clinical safety studies based on 30 026 post-marketing cases of Shenqi Fuzheng injection by intensive hospital monitoring nested NCCS].
Wang LX; Xie YM; Ai QH; Xu WF
Zhongguo Zhong Yao Za Zhi; 2015 Dec; 40(24):4739-45. PubMed ID: 27245015
[TBL] [Abstract][Full Text] [Related]
29. [A discussion of key issues on postmarketing reevaluation of Chinese medicine].
Xie Y; Tian F
Zhongguo Zhong Yao Za Zhi; 2010 Jun; 35(11):1494-7. PubMed ID: 20822029
[TBL] [Abstract][Full Text] [Related]
30. [Post-marketing safety surveillance of Diemailing Kudiezi injection: real world study in 30 233 cases].
Liao X; Yu DD; Xie YM; Zhang YL; He Y; Zhang Y; Liu Y; Yi DH; Wang YY
Zhongguo Zhong Yao Za Zhi; 2017 Aug; 42(15):2857-2863. PubMed ID: 29139248
[TBL] [Abstract][Full Text] [Related]
31. [Post-marketing surveillance of
Li XX; Zhuo L; Yang YH; Zhan SY; Zhai SD
Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Feb; 38(2):248-252. PubMed ID: 28231676
[No Abstract] [Full Text] [Related]
32. [Clinical orientation of post-marketing Chinese patent drugs: an evidence-based practice].
Shang HC; Zhang BL; Li YP
Zhong Xi Yi Jie He Xue Bao; 2008 Sep; 6(9):887-90. PubMed ID: 18782528
[TBL] [Abstract][Full Text] [Related]
33. [Discussion on methods of sample size estimation in conducting clinical reevaluation of postmarketing Chinese medicine].
Tian F; Fu Y; Xie Y
Zhongguo Zhong Yao Za Zhi; 2011 Apr; 36(8):1097-102. PubMed ID: 21809593
[TBL] [Abstract][Full Text] [Related]
34. [Comparative study on four kinds of assessment methods of post-marketing safety of Danhong injection].
Li X; Tang J; Meng F; Li C; Xie Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2786-8. PubMed ID: 22292365
[TBL] [Abstract][Full Text] [Related]
35. [Interpretation of adverse drug reaction reporting and monitoring and significance of traditional Chinese medicine adverse drug reaction monitoring].
Wang D; Du XX
Zhongguo Zhong Yao Za Zhi; 2012 Sep; 37(18):2686-8. PubMed ID: 23285908
[TBL] [Abstract][Full Text] [Related]
36. [Spontaneous reporting system data analysis of parenterally administered Shenmai].
Wang LX; Xiang YY; Xie YM; Shen H; Ai QH
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2987-93. PubMed ID: 24471317
[TBL] [Abstract][Full Text] [Related]
37. [Safety of medicinal products and reporting of adverse drug reactions].
Skibicka I; Maciejczyk A
Neurol Neurochir Pol; 2004; 38(6):503-10. PubMed ID: 15654675
[TBL] [Abstract][Full Text] [Related]
38. [Survey on Xiaoke pill treating diabetes mellitus in small cities' Chinese medicine hospital for post-marketing surveillance].
Xie Y; Zhao Y; Liu H; Wang Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2859-61. PubMed ID: 22292385
[TBL] [Abstract][Full Text] [Related]
39. [Postmarketing herbs clinical evaluation should concern about re-evaluating symptoms].
He W; Xie Y; Wang Y
Zhongguo Zhong Yao Za Zhi; 2010 Jun; 35(11):1498-500. PubMed ID: 20822030
[TBL] [Abstract][Full Text] [Related]
40. Establishment of safety evidence for Xingxue Shuxuening injection.
Yang W; Zhang W; Xie Y; Han B
J Tradit Chin Med; 2014 Oct; 34(5):604-8. PubMed ID: 25417413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
